![examples of cataplexy examples of cataplexy](https://freemedicalvideos.com/wp-content/uploads/2017/05/narcolepsy-causes-symptoms-diagnosis-treatment-pathology-youtube-thumbnail.jpg)
![examples of cataplexy examples of cataplexy](https://image.slidesharecdn.com/sleepdisorder-140706105844-phpapp01/95/sleep-disorder-15-638.jpg)
Globally, narcolepsy affects approximately 0.02% of adults, with great variations in prevalence, attributed to differences in the genetic background. 1, 2 Narcolepsy is categorized into two types, narcolepsy type 1 (NT1) (with cataplexy) and narcolepsy type 2 (NT2) (without cataplexy). Usually, narcolepsy manifestations appear in the second decade of life however, it may present during childhood. 1 Additionally, disturbed, fragmented nighttime sleep is one of the prominent features of narcolepsy. Narcolepsy is a chronic neurological disorder affecting sleep/wakefulness regulation and causing irresistible attacks of sleep and manifestations of various rapid eye movement (REM) sleep abnormalities, including cataplexy, sleep paralysis, and hypnagogic hallucinations. Keywords: body mass index, sleep quality, daytime sleepiness, Pittsburgh Sleep Quality IndexĬorrigendum for this paper has been published More prospective studies that repeatedly monitor CSF-HCRT are needed to confirm the current findings. Over a 10-year period, cataplexy symptoms improved or disappeared in a large proportion of patients, and there was an improvement in daytime sleepiness and nighttime sleep quality.
![examples of cataplexy examples of cataplexy](http://image.slidesharecdn.com/psya3sleep-130528173928-phpapp02/95/psya3-sleep-2-638.jpg)
No changes were documented in comorbidities.Ĭonclusion: The findings suggest that the course of NT1 is not stable. The number of patients with a PSQI score of < 5 (indicating good sleep quality) increased from 6 (15.8%) to 15 (39.5%) (p=0.004). The mean ESS score decreased by more than 4 points from 19.4 ± 2.9 to 15 ± 4.3 (p< 0.001) while on the same pharmacotherapy. Additionally, there was an apparent significant reduction in the frequency of cataplexy over time. Results: In 42% of the cohort, the anti-cataplectic medications were stopped at the end of the study without disturbing symptoms of cataplexy. The mean ages at disease onset and recruitment were 17.7 ± 5.6 years and 24.3 ± 8.6 years, respectively. The study sample comprised 38 patients with narcolepsy (males=27). Patients and methods: Cataplexy symptoms, the Epworth sleepiness scale (ESS), sleep quality (assessed using the Pittsburgh sleep quality index ), BMI, and comorbid conditions were prospectively monitored in 38 patients with NT1. Other secondary objectives included assessing sleep quality, body mass index (BMI), and comorbidities at recruitment and 10 years later.
![examples of cataplexy examples of cataplexy](https://www.hypersomniafoundation.org/wp-content/uploads/2015/06/PSG.png)
This study aimed to assess the natural course of cataplexy in patients with NT1 at 2, 6, and 10 years after stabilizing symptoms. Purpose: Narcolepsy type 1 (NT1) is thought to have a chronic persistent course. Sleep Disorders Center, College of Medicine, King Saud University, Box 225503, Riyadh 11324, Saudi ArabiaĮmail Aljohara S Almeneessier, 1, 2 Nouf S Alballa, 1 Budoor H Alsalman, 1 Salih Aleissi, 1 Awad H Olaish, 1 Ahmed S BaHammam 1ġDepartment of Medicine, College of Medicine, the University Sleep Disorders Center, Riyadh, Saudi Arabia 2Family and Community Medicine Department, College of Medicine, King Saud University, Riyadh, Saudi ArabiaĬorrespondence: Ahmed S BaHammam Aljohara S Almeneessier